Trastuzumab, commonly known as Herceptin, is a monoclonal antibody used to treat HER2-positive breast cancer and gastric cancer. As the patent expiration for trastuzumab approaches, the biosimilar market is gaining momentum. Biosimilars are biologic medical products highly similar to an already approved reference product, offering similar efficacy and safety but at a potentially lower cost.
https://www.delveinsight.com/r....eport-store/trastuzu
Like
Comment
Share
